Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)

Prerandomization Inclusion Criteria: * Provide written informed consent before initiation of any study related procedures. * Be at least 18 years of age * Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery Prerandomization Exclusion Criteria: * Women of child-bearing potential (unless they have a negative pregnancy test) * Recent cerebrovascular accident (within 3 months before randomization) * Known intolerance to calcium channel blockers * Known or suspected hypersensitivity to nicardipine * Allergy to soybean oil or egg lecithin (components of the lipid vehicle) * Pre-existing permanent ventricular pacing * Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial * Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study Postrandomization Inclusion Criteria: * Expected to survive beyond 24 hours post-surgical procedure * No surgical complications or conditions, present or anticipated, that preclude them from inclusion in the study * Determined to be hypertensive postoperatively as determined by the investigator